Symbiotec Pharmalab is set to open its Initial Public Offering (IPO) for subscription on August 24, 2026, with the bidding period scheduled to remain open until August 27, 2026.

The company has fixed the IPO price band at INR 938 to INR 988 per equity share, with a minimum bid of 15 equity shares and in multiples of 15 shares thereafter. Eligible employees participating in the employee reservation portion will be offered a discount of INR 90 per equity share, with each share having a face value of INR 2.

The Anchor Investor bidding period will open and close on August 21, 2026, ahead of the public subscription.

The net proceeds from the fresh issue are proposed to be used primarily for the prepayment and/or repayment, in full or in part, of certain outstanding borrowings of Symbiotec Pharmalab. The remaining proceeds will be utilised for general corporate purposes.

The offer also includes an Offer for Sale (OFS) by the promoter and investor selling shareholders. Under the OFS, Satwani Holdings, the promoter selling shareholder, will offer equity shares aggregating up to INR 144 crore. Investor selling shareholders Rosewood Investments and India Business Excellence Fund – III will offer shares aggregating up to INR 988 crore and INR 475 crore, respectively.

The total value of the OFS component is therefore up to INR 1,607 crore.

The equity shares are being offered through the company's Red Herring Prospectus dated August 18, 2026, filed with the Registrar of Companies, Madhya Pradesh at Gwalior.

Following the IPO, the equity shares are proposed to be listed on BSE (BSE) and the National Stock Exchange of India (NSE). BSE has been designated as the Designated Stock Exchange for the offer.

JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India) are acting as the Book Running Lead Managers to the IPO.

The IPO represents an important capital markets milestone for Symbiotec Pharmalab as the company seeks to strengthen its financial position through debt reduction while providing an exit opportunity to existing promoter and investor shareholders.